A method for treating hypoparathyroidism and/or hypocalcemia by local administration of a neurotoxin, such as a botulinum toxin, to a parathyroid gland, thereby reducing an inhibitory effect upon parathyroid hormone secretion. A method for treating hyperparathyroidism and/or hypercalcemia by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates a parathyroid hormone secreting parathyroid cell, thereby reducing a stimulatory effect upon parathyroid hormone secretion.

Un metodo per trattare hypoparathyroidism e/o hypocalcemia tramite la gestione locale di una neurotossina, quale una tossina botulina, ad una ghiandola paratiroidale, quindi riducente un effetto inibitorio sulla secrezione paratiroidale dell'ormone. Un metodo per trattare hyperparathyroidism e/o hypercalcemia tramite la gestione locale di una neurotossina, quale una tossina botulina, ad un ganglion simpatico che innervates una cellula paratiroidale di secrezione dell'ormone paratiroidale, quindi riducente un effetto stimolatore sulla secrezione paratiroidale dell'ormone.

 
Web www.patentalert.com

< Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives

< Nutrient formulations for disease reduction

> Hypoparathyroid therapy

> Gastric retaining oral liquid dosage form

~ 00091